Гормонотерапия в акушерстве и гинекологии. Иллюзии и реальность

Henriet P., Chevronnay H. P. G., Marbaix E. The endocrine and paracrine control of menstruation. Molecular and Cellular Endocrinology, 2012; 358:197–207.

Hensleigh P. A., Fainstat T. Corpus luteum dysfunction: serum progesterone levels in diagnosis and assessment of therapy for recurrent and threatened abortion. Fertil. Steril., 1979; 32:715–719.

Hermann A. C., et al. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. J. Clin. Pharmacol., 2005; 45:614–619.

Hermann W. L., Schlindler A. M. Wyss R., Bischoff P. Effects of anti-progesterone RU 486 in early pregnancy and during the menstrual cycle. In: Beaulieu E. E., Siegel S., editors. The Antiprogestin Steroid RU 486 and Human Fertility Control. New York: Plenum; 1985; 259–262.

Hertig A. T. Allen and Doisy’s ’An Ovarian Hormone’. JAMA, 1983; 250 (19):2684–2688.

Herzog A. G. Hormonal Therapies: Progesterone Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 2009; 6:383–391.

Herzog A. G. Progesterone therapy in complex partial and secondary generalized seizures. Neurology, 1995; 45:1660–1662.

Herzog A. G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology, 1999; 52:1917–1918.

Hewedi I. H., et al. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. Diagnostic Pathology, 2012; 7:1.

Hibbert M. L., et al. Midcycle administration of a progesterone synthesis inhibitor prevents ovulation in primates. Proceedings of the National Academy of Sciences of the United States of America, 1996; 93:1897–1901.

Hickey M., et al. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. J. Clin. Endocrinol. Metab., 2006; 91:3633–3638.

Hicks C. W., Rome E. S. Menstrual manipulation: Options for suppressing the cycle. Cleveland Clinical Journal of Medicine, 2010; 77 (7):445–453.

Hidalgo M., et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002; 65:129–132.

Hildebrand M. S., et al. Genetic male infertility and mutation of CATSPER ion channels. Eur. J. Hum. Genet., 2010; 18:1178–1184.

Hileman S. M., Pierroz D. D., Flier J. S. Leptin, Nutrition, and Reproduction: Timing is Everything. J. Clin. Endocrinol. Metab., 2000; 85:804–807.

Hill M., et al. Reduced Progesterone Metabolites in Human Late Pregnancy. Physiol. Res., 2011; 60:225–241.

Hill P., et al. Diet and follicular development. Am. J. Clin. Nutr., 1984; 39:771–777.

Hillard P. Menstruation in adolescents, what’s normal, what’s not. Ann. N. Y. Acad. Sci., 2008; 1135:29–35.

Hillier S. G. Sex steroid metabolism and follicular development in the ovary. Oxf. Rev. Reprod. Biol., 1985; 7:168–222.

Hillman D. Fetal masculinization with maternal progesterone therapy. Can. M. A. J., 1959; 80:200–201.

Hodges Y. K., et al. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation, 1999; 99 (20):2688–2693.

Hofmann G. E., et al. Evaluation of the reproductive performance of womenwith elevated day 10 progesterone levels during ovarian reserve screening. Fertil. Steril., 1995; 63:979–983.

Holmes P. V., et al. Effects of high and low preovulatory concentrations of progesterone on ovulation from the isolated perfused rabbit ovary. J. Reprod. Fertil., 1985; 75,393–399.

Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgrad. Med., 2009; 121:73–85.

Homan G., et al. Human chorionic gonadotropin as a predictor of outcome in assisted reproductive technology pregnancies. Fertil. Steril., 2000; 73:270–274.

Hopp T. A., et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clinical Cancer Research, 2004; 10:2751–2760.

Horta J. L., et al. Direct evidence of luteal insufficiency in women with habitual abortion. Obstet. Gynecol., 1977; 49:705–708.

Hsieh C. C., et al. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international casecontrol study. Int. J. Cancer, 1990; 46:796–800.

Huber J. C., Ott J. The dialectic role of progesterone. Maturitas, 2009; 62:326–329.

Hudson R., Pharriss B. B., Tillson S. A. Preclinical evaluation of intrauterine progesterone as a contraceptive agent. III. Embryology and toxicology. Contraception, 1978; 17:489–497.

Hughes G. C. Progesterone and autoimmune disease. Autoimmunity Reviews, 2012; 11:A502–A514.

Hugues J. N. Impact of ’LH activity’ supplementation on serum progesterone levels during controlled ovarian stimulation: a systematic review. Human Reproduction, 2012; 27 (1):232–243.